Skip to content
← Full study record

NCT00941720 · OUTCOME

Pulmonary Toxicity

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma · Source last updated 2020-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
At 6 months

What was measured

Toxicity criteria will be assessed and graded according to the National Cancer Institute (NCI) Common Terminology Criteria (CTC) v3.0. Estimated using exact 95% binomial confidence intervals.

Groups in this outcome

Busulfan Treatment

busulfan: IV busulfan 0.8 mg/kg every 6 hours x 16 doses cyclophosphamide: IV cyclophosphamide 60 mg/kg over 4 hours x 2 days autologous hematopoietic stem cell transplantation: infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Busulfan Treatment57

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Busulfan Treatment3.5Not reported0.412.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.4
        upper Limit
        12.1
        value
        3.5
denoms
  1. counts
    1. group Id
      OG000
      value
      57
    units
    Participants
description
Toxicity criteria will be assessed and graded according to the National Cancer Institute (NCI) Common Terminology Criteria (CTC) v3.0. Estimated using exact 95% binomial confidence intervals.
dispersion Type
95% Confidence Interval
groups
  1. description
    busulfan: IV busulfan 0.8 mg/kg every 6 hours x 16 doses cyclophosphamide: IV cyclophosphamide 60 mg/kg over 4 hours x 2 days autologous hematopoietic stem cell transplantation: infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
    id
    OG000
    title
    Busulfan Treatment
param Type
NUMBER
reporting Status
POSTED
time Frame
At 6 months
title
Pulmonary Toxicity
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice